Genovis AB (publ.) (FRA:5GV)

Market Cap	127.73M -8.5%
Revenue (ttm)	12.27M +11.2%
Net Income	1.85M -24.0%
EPS	0.03 -24.8%
Shares Out	n/a
PE Ratio	63.82
Forward PE	56.02
Dividend	n/a
Ex-Dividend Date	n/a

Volume	600
Open	1.776
Previous Close	1.776
Day's Range	1.776 - 1.776
52-Week Range	1.414 - 2.125
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 10, 2026

About Genovis AB (publ.)

Genovis AB (publ.) develops and sells tools for the development of new treatment methods and diagnostics in North America, Europe, and Asia. The company provides FabRICATOR, FabALACTICA, FabRICATOR Z, GingisKHAN, FabULOUS (SpeB), a cysteine protease; FabDELLO, a protease that digests human IgG1; IgASAP, an IgA-digesting enzyme; and IgMBRAZOR, an IgM-specific protease. It also offers GlySERIAS, an enzyme that digests flexible glycine-rich fusion protein linkers; GlyCLICK, a conjugation technology; TransGLYCIT, a platform technology; and GingisRE...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 42
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 5GV

Financial Performance

In 2025, Genovis AB (publ.)'s revenue was 129.23 million, a decrease of -1.06% compared to the previous year's 130.61 million. Earnings were 23.50 million, a decrease of -28.61%.

Financial numbers in SEK

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Oct 26, 2026

Data Sources Report a data error